Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple
CD38
Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?
American Journal of Hematology | January 27, 2026 | Volume: 101 | Issue: 5 | Pages: 1141-1147
10.1002/ajh.70215
| PMID 41588844